AN ACT relating to public health and declaring an emergency.

WHEREAS, in September 2000, the Food and Drug Administration (FDA) approved the distribution and use of mifepristone (brand name mifeprex), originally referred to as "RU-486", an abortion-inducing drug, under the authority of 21 C.F.R. 314.520, also referred to as "Subpart H," which is the only FDA approval process that allows for post-marketing restrictions. Specifically, the Code of Federal Regulations provides for accelerated approval of certain drugs that are shown to be effective but "can be safely used only if distribution or use is restricted"; and

WHEREAS, the FDA does not treat Subpart H drugs in the same manner as drugs that undergo the typical approval process, giving them heightened scrutiny after approval; and

WHEREAS, in September 2000, the FDA prescribed a specific gestation of 49 days from the last menstrual period (LMP), dosage, and administration protocol for mifeprex/mifepristone; and

WHEREAS, the approved FDA protocol for mifeprex/mifepristone was modified in March 2016 and maintains that certain distribution restrictions are still necessary because of the drug’s potential for serious complications; and

WHEREAS, as approved by the FDA, the 2016 administration protocol consists of one 200 mg tablet in a single oral dose of mifeprex/mifepristone followed by four 200 mcg tablets misoprostol taken 24 to 48 hours later in the cheek pouch, through 70 days LMP. The patient is to return for a follow-up visit to confirm that a complete abortion has occurred 7 to 14 days after administration of the abortion-inducing drug; and

WHEREAS, the 2016 FDA protocol also requires that the distribution and use of mifeprex/mifepristone be under the supervision of a qualified healthcare provider who has the ability to assess the duration of pregnancy, diagnose ectopic pregnancies, and provide surgical intervention or has made plans to provide surgical intervention through another qualified physician; and
WHEREAS, on December 16, 2021, the FDA announced that it will no longer require an in-person medical examination, it will permit abortion-inducing drugs to be mailed to the patient, and it will permit pharmacies to fill prescriptions if they are certified by the manufacturers to do so; and

WHEREAS, court testimony by Planned Parenthood and other abortion providers has demonstrated that providers routinely and intentionally failed to follow the September 2000 FDA-approved protocol for mifeprex/mifepristone (for example, see Planned Parenthood Cincinnati Region v. Taft, 459 F. Supp. 2d 626, S.D. Oh. 2006); and

WHEREAS, the use of mifeprex/mifepristone presents significant medical risks, including but not limited to uterine hemorrhage, viral infections, abdominal pain, cramping, vomiting, headache, fatigue, and pelvic inflammatory disease; and

WHEREAS, health problems usually do not occur during the first pregnancy for an Rh negative woman with an Rh positive fetus because the body does not have a chance to develop a large number of antibodies; and

WHEREAS, if the woman is Rh negative and does not receive an injection of Rh immunoglobulin at the time of an abortion or delivery, she may experience Rh incompatibility in future pregnancies which can lead to complications and miscarriage. Therefore, it is critical for a qualified physician to determine blood type and administer Rh immunoglobulin if a woman is Rh negative; and

WHEREAS, the risk of complications increases with advancing gestational age and with the failure to either complete the two-step dosage process for the mifeprex/mifepristone regimen or to receive abortion pill reversal care from a qualified healthcare professional; and

WHEREAS, studies document that increased rates of complications, including incomplete abortion, occur even within the FDA-approved gestational limit; and

WHEREAS, as of March 2020, the FDA reported 4,480 adverse events after women used mifeprex/mifepristone for abortions. Among these events were 24 deaths,
1,183 hospitalizations, 339 blood transfusions, and 256 infections, including 48 severe
infections; and

WHEREAS, the Adverse Event Reports (AER) systems relied upon by the FDA
have limitations and typically detect only a small proportion of events that actually occur;
and

WHEREAS, as of March 31, 2020, 27 women have reportedly died after
administration of mifeprex/mifepristone, with 6 deaths attributed to severe bacterial
infections. Eight of those women administered the mifeprex/mifepristone regimen in an
"off-label" or "evidence-based" manner then-advocated by abortion providers, and the
FDA has not been able to determine whether this off-label use led to the deaths; and

WHEREAS, medical evidence demonstrates that women who use abortion-inducing
drugs risk four times more complications than those who undergo surgical abortions. At
least three to eight percent of medical abortions fail to evacuate the pregnancy tissue and
require surgical completion. One percent will fail to kill the fetus. If surgical completion
is required after a failed medical abortion, the risk of premature delivery in a subsequent
pregnancy is more than three times higher. Failure rates increase as gestational age
increases. The gestational age range of 63 to 70 days has been inadequately studied. The
2016 FDA gestational age extension was based on only one study worldwide of little
more than 300 women; and

WHEREAS, 2020 marked the state of Arkansas’ first full year of data after a new
abortion complication reporting law went into effect. Forty-five complications were
reported in 2020, of which 40, or 88 percent of all complications, resulted from chemical
abortions; and

WHEREAS, a woman’s ability to provide informed consent depends on the extent
to which the woman receives information sufficient to make an informed choice; and

WHEREAS, the decision to abort "is an important, and often a stressful one, and it
is desirable and imperative that it be made with full knowledge of its nature and
consequences” as stated in Planned Parenthood v. Danforth, 428 U.S. 52, 67 (1976); and

WHEREAS, some women come to regret their decision to abort shortly after ingesting mifeprex/mifepristone; and

WHEREAS, in recent years, physicians have developed a method to potentially reverse the effects of mifeprex/mifepristone. This abortion pill reversal or rescue process has been discussed in a peer-reviewed study and is based on decades of the safe use of progesterone to stabilize and continue pregnancies; and

WHEREAS, understanding the science behind the mechanism of action of mifeprex/mifepristone has allowed physicians to design a specific rescue for a woman who has used mifeprex/mifepristone to induce an abortion but has not yet ingested the second drug in the chemical abortion regimen. Since physicians know that mifeprex/mifepristone works by blocking progesterone, physicians know that treating a woman with progesterone can displace mifeprex/mifepristone from the progesterone receptors. This allows the woman's body to respond naturally to the progesterone and to effectively fight the effects of the mifeprex/mifepristone-induced blockage; and

WHEREAS, it has long been known that mifepristone acts reversibly at the molecular level of receptor binding. Progesterone and mifepristone compete for the binding site of the receptor making the anti-progesterone activity of mifepristone reversible; and

WHEREAS, mifeprex/mifepristone floods the progesterone receptors, blocking progesterone. Progesterone reverses the effects of the mifeprex/mifepristone by outcompeting and outnumbering the mifepristone and restoring adequate progesterone to sustain the pregnancy; and

WHEREAS, progesterone itself has been used safely during pregnancy for decades. It is used in in-vitro fertilization, infertility treatments, and high-risk pregnancies such as pre-term labor. Using progesterone to reverse the effects of mifeprex/mifepristone is a targeted response that is safe for women; and
WHEREAS, statistics show that as of March 2020, more than 1,000 lives have been
saved following the progesterone reversal process and that babies born following the
reversal process have a rate of birth defects no higher than the general population; and

WHEREAS, studies show that following the progesterone reversal process or
otherwise treating a woman with progesterone during pregnancy does not lead to
increased mortality rates; and

WHEREAS, to facilitate reliable scientific studies and research on the safety and
efficacy of abortion-inducing drugs, it is essential that the medical and public health
communities have access to accurate information both on the efficacy and use of
abortion-inducing drugs, as well as on resulting complications; and

WHEREAS, abortion "record keeping and reporting provisions that are reasonably
directed to the preservation of maternal health and that properly respect a patient’s
confidentiality and privacy are permissible" as stated in Planned Parenthood v. Danforth,
428 U.S. 80 at 52, 79-81 (1976); and

WHEREAS, abortion and complication reporting provisions do not impose an
"undue burden" on a woman’s right to choose whether or not to terminate a pregnancy.
Specifically, "[t]he collection of information with respect to actual patients is a vital
element of medical research, and so it cannot be said that the requirements serve no
purpose other than to make abortions more difficult" as stated in Planned Parenthood v.
Casey, 505 U.S. 833 at 900-901 (1992); and

WHEREAS, to promote its interest in maternal health and life, the Commonwealth
of Kentucky has an interest in collecting demographic information on all drug-induced
abortions performed and all abortion complications from all drug-induced abortions
diagnosed or treated and compiling statistical reports based on the information collected
for future scientific studies and public health research; and

WHEREAS, based on the findings from scientific studies and public health
research, it is the purpose of this Act to:
1. Protect the health and welfare of every woman considering a drug-induced abortion;

2. Ensure that a physician examines a woman prior to dispensing an abortion-inducing drug in order to confirm the gestational age of the unborn child, the intrauterine location of the unborn child, and that the unborn child is alive, since routine administration of mifepristone following spontaneous miscarriage is unnecessary and exposes the woman to unnecessary risks associated with both mifepristone and misoprostol;

3. Ensure that a physician does not prescribe or dispense an abortion-inducing drug beyond 70 days’ gestation;

4. Reduce "the risk that a woman may elect an abortion, only to discover later, with devastating psychological consequences, that her decision was not fully informed." Planned Parenthood v. Casey, 505 U.S. 833, 882 (1992);

5. Ensure that women considering a drug-induced abortion receives comprehensive information on abortion-inducing drugs, including the potential to reverse the effects of the drugs should she change her mind, and that women submitting to an abortion does so only after giving her voluntary and fully informed consent to the procedure; and

6. Promote the health and safety of women, by adding to the sum of medical and public health knowledge through the compilation of relevant data on drug-induced abortions performed in the state, as well as on all medical complications and maternal deaths resulting from these abortions; and

WHEREAS, sexually transmitted diseases (STDs) are usually spread by having vaginal, oral, or anal sex. More than 9 million women in the United States are diagnosed with an STD each year, and women often have more serious health problems associated with STDs than men, including infertility; and

WHEREAS, the primary goal of the Kentucky Sexually Transmitted Disease
Prevention and Control Program is to prevent the spread and complications of STDs; and

WHEREAS, local health departments test for chlamydia, gonorrhea, and syphilis, and provide treatment for individuals diagnosed with, exposed to, or suspected of having these diseases; and

WHEREAS, chlamydia and gonorrhea, left untreated, increase the risk of chronic pelvic pain and life-threatening ectopic pregnancy and untreated syphilis in pregnant women results in infant death up to 40 percent of the time; and

WHEREAS, women have a higher risk than men of getting an STD during unprotected sex; and

WHEREAS, since women and girls seeking to terminate an unplanned pregnancy may have had limited encounters with a healthcare provider prior to their encounter with an abortion providing facility, it is in the best interest of improving health outcomes for all Kentucky women and girls to ensure women and girls have the opportunity to receive timely and accurate information on women’s health risks, especially Rh negative and STDs, that may impact their future health, the health of their partners and future pregnancies, and increase the risk of harmful fetal and child health outcomes; and

WHEREAS, despite spending on health care in the United States far outpacing other nations, health outcomes are often much worse, particularly for women, because the focus in the United States has been on treating discrete, acute conditions and procedures rather than coordinating care, providing preventive services, and addressing root causes of poor health; and

NOW, THEREFORE,

Be it enacted by the General Assembly of the Commonwealth of Kentucky:

Section 1. KRS 311.732 is amended to read as follows:

(1)  For purposes of this section the following definitions shall apply:

(a) "Minor" means any person under the age of eighteen (18);

(b) "Emancipated minor" means any minor who is or has been married or has by
court order or otherwise been freed from the care, custody, and control of her
parents; and

(c) "Abortion" means the use of any instrument, medicine, drug, or any other
substance or device with intent to terminate the pregnancy of a woman known
to be pregnant with intent other than to increase the probability of a live birth,
to preserve the life or health of the child after live birth, or to remove a dead
fetus.

(2) No person shall perform an abortion upon a minor unless:

(a) The attending physician[ or his agent] has secured the informed written
consent of the minor and one (1) parent or legal guardian with joint or
physical custody and the consenting parent or legal guardian of the minor
has made a reasonable attempt to notify any other parent with joint or
physical custody at least forty-eight (48) hours prior to providing the
informed written consent.

1. Notice shall not be required to be provided to any parent who has:

   a. Previously been enjoined by a domestic violence order or
      interpersonal protective order, regardless of whether or not the
      person to be protected by the order was the minor; or
   
   b. Been convicted of, or entered into a diversion program for, a
      criminal offense against a victim who is a minor as defined in
      KRS 17.500 or for a violent or sexual criminal offense under
      KRS Chapter 506, 507, 507A, 508, 509, 510, 529, 530, or 531.

2. The informed written consent shall include:

   a. A copy of the minor's government-issued identification, a copy of
      the consenting parent's or legal guardian's government-issued
      identification, and written documentation including but not
      limited to a birth certificate, court-ordered custodial paperwork.
or tax return, establishing that he or she is the lawful parent or legal guardian; and

b. The parent's or legal guardian's certification that he or she consents to the abortion. The certification shall be in a signed, dated, and notarized document that has been initialed on each page and that contains the following statement, which shall precede the signature of the parent or legal guardian: "I, (insert name of parent or legal guardian), am the (select "parent" or "legal guardian") of (insert name of minor) and give consent for (insert name of attending physician) to perform an abortion on her. Under penalties of perjury, I declare that I have read the foregoing statement and that the facts stated in it are true."

3. The attending physician shall keep a copy of the informed written consent in the medical file of the minor for five (5) years after the minor reaches eighteen (18) years of age or for seven (7) years, whichever is longer.

4. The attending physician securing the informed written consent from a parent or legal guardian under this subsection shall execute for inclusion in the medical record of the minor an affidavit stating: "I, (insert name of attending physician), certify that, according to my best information and belief, a reasonable person under similar circumstances would rely on the information presented by both the minor and her parent or legal guardian as sufficient evidence of identity."

(b) The minor is emancipated and the attending physician[ or his agent] has received the informed written consent of the minor; or

(c) The minor elects to petition any Circuit or District Court of the
Commonwealth pursuant to subsection (3) of this section and obtain an order pursuant to subsection (4) of this section granting consent to the abortion and the attending physician[ or his agent] has received the informed written consent of the minor.

(3) Every minor shall have the right to petition any Circuit or District Court of the Commonwealth for an order granting the right to self-consent to an abortion pursuant to the following procedures:

(a) The minor or her next friend may prepare and file a petition setting forth the request of the minor for an order of consent to an abortion;

(b) The court shall ensure that the minor prepares or her next friend is given assistance in preparing and filing the petition and shall ensure that the minor's identity is kept anonymous;

(c) The minor may participate in proceedings in the court on her own behalf or through her next friend and the court shall appoint a guardian ad litem for her. The court shall advise her that she has a right to court-appointed counsel and shall provide her with such counsel upon her request;

(d) All proceedings under this section shall be anonymous and shall be given preference over other matters to ensure that the court may reach a decision promptly, but in no case shall the court fail to rule within seventy-two (72) hours of the time of application, provided that the seventy-two (72) hour limitation may be extended at the request of the minor; and

(e) The court shall hold a hearing on the merits of the petition before reaching a decision. The court shall hear evidence at the hearing relating to:

1. **The minor’s:**
   a. **Age:**
   b. [The] Emotional development **and stability:**
   c. **Maturity**

Page 10 of 60

HB000330.100 - 343 - XXXX

House Committee Substitute
d. Intellect[, and understanding of the minor];

e. Credibility and demeanor as a witness;

f. Ability to accept responsibility;

g. Ability to assess both the current and future life-impacting[the nature, possible] consequences of, and alternatives to, the abortion; and

h. Ability to understand and explain the medical risks of the abortion and to apply that understanding to her decision; and

2. Whether there may be any undue influence by another on the minor's decision to have an abortion[any other evidence that the court may find useful in determining whether the minor should be granted majority rights for the purpose of consenting to the abortion or whether the abortion is in the best interest of the minor].

(4) (a) If the court finds by:

1. Clear and convincing evidence that the minor is sufficiently mature to decide whether to have an abortion;

2. Clear and convincing evidence that the requirements of this section are not in the best interest of the minor; or

3. A preponderance of the evidence that the minor is the victim of child abuse or sexual abuse inflicted by one (1) or both of her parents or her legal guardian:

the court shall enter a written order, making specific factual findings and legal conclusions supporting its decision to grant the petition for an abortion[as follows: —]

(b) If the court does not make any of the findings specified in paragraph (a) of this subsection, the court shall deny the petition[(a) — Granting the petition for an abortion if the court finds that the minor is mature and well informed...}
enough to make the abortion decision on her own;

(b) Granting consent to the abortion if the court finds that the performance of the abortion would be in the minor's best interest; or

(c) Deny the petition, if the court finds that the minor is immature and that performance of the abortion would not be in the minor's best interest].

(c) As used in this subsection, "best interest of the minor" shall not include financial best interest, financial considerations, or the potential financial impact on the minor or the minor's family if the minor does not have an abortion.

(5) Any minor shall have the right of anonymous and expedited appeal to the Court of Appeals, and that court shall give precedence over other pending matters.

(6) All hearings under this section, including appeals, shall remain confidential and closed to the public. The hearings shall be held in chambers or in a similarly private and informal setting within the courthouse.

(7) No fees shall be required of any minor who declares she has no sufficient funds to pursue the procedures provided by this section.

(8) The Supreme Court is respectfully requested to promulgate any rules and regulations it feels are necessary to ensure that proceedings under this section are handled in an expeditious and anonymous manner.

(b) The Supreme Court, through the Administrative Office of the Courts, shall report by February 1 of each year to the Legislative Research Commission and the cabinet on the number of petitions filed under subsection (3) of this section for the preceding year, and the timing and manner of disposal of the petition by each court. For each approved petition granting an abortion filed under subsection (3) of this section, the specific court finding in subsection (4) of this section shall be included in the report.

(9) The requirements of subsections (2), (3), and (4) of this section shall not
apply when, in the best medical judgment of the physician based on the facts
of the case before him, a medical emergency exists that so complicates the
pregnancy as to require an immediate abortion.

(b) If a medical emergency exists, the physician shall make reasonable
attempts, whenever possible, and without endangering the minor, to contact
the parent or legal guardian of the minor, and may proceed, but must
document reasons for the medical necessity in the minor's medical records.

(c) The physician shall inform the parent or legal guardian, in person or by
telephone, within twenty-four (24) hours of the abortion, including details
of the medical emergency that necessitated the abortion without the parent's
or legal guardian's consent. The physician shall also provide this
information in writing to the parent or legal guardian at his or her last
known address by first-class mail or by certified mail, return receipt
requested, with delivery restricted to the parent or legal guardian. A
physician who does not comply with subsection (2), (3), or (4) of this section
due to the utilization of this exception shall certify in writing the medical
indications upon which his judgment was based.

A report indicating the basis for any medical judgment that warrants failure to
obtain consent pursuant to this section shall be filed with the Cabinet for Health and
Family Services on a form supplied by the cabinet. This report shall be confidential.

Failure to obtain consent pursuant to the requirements of this section is prima
facie evidence of failure to obtain informed consent and of interference with family
relations in appropriate civil actions. The law of this state shall not be construed to
preclude the award of exemplary damages in any appropriate civil action relevant to
violations of this section. Nothing in this section shall be construed to limit the
common-law rights of parents.

A minor upon whom an abortion is performed is not guilty of violating this
Section 2. KRS 311.595 is amended to read as follows:

If the power has not been transferred by statute to some other board, commission, or agency of this state, the board may deny an application or reregistration for a license; place a licensee on probation for a period not to exceed five (5) years; suspend a license for a period not to exceed five (5) years; limit or restrict a license for an indefinite period; or revoke any license heretofore or hereafter issued by the board, upon proof that the licensee has:

(1) Knowingly made or presented, or caused to be made or presented, any false, fraudulent, or forged statement, writing, certificate, diploma, or other thing, in connection with an application for a license or permit;

(2) Practiced, or aided or abetted in the practice of fraud, forgery, deception, collusion, or conspiracy in connection with an examination for a license;

(3) Committed, procured, or aided in the procurement of an unlawful abortion, including a partial-birth abortion or an abortion in violation of KRS 311.731;

(4) Entered a guilty or nolo contendere plea, or been convicted, by any court within or without the Commonwealth of Kentucky of a crime as defined in KRS 335B.010, if in accordance with KRS Chapter 335B;

(5) Been convicted of a misdemeanor offense under KRS Chapter 510 involving a patient, or a felony offense under KRS Chapter 510, 530.064(1)(a), or 531.310, or been found by the board to have had sexual contact as defined in KRS 510.010(7) with a patient while the patient was under the care of the physician;

(6) Become addicted to a controlled substance;

(7) Become a chronic or persistent alcoholic;

(8) Been unable or is unable to practice medicine according to acceptable and prevailing standards of care by reason of mental or physical illness or other condition including but not limited to physical deterioration that adversely affects
cognitive, motor, or perceptive skills, or by reason of an extended absence from the
active practice of medicine;

(9) Engaged in dishonorable, unethical, or unprofessional conduct of a character likely
to deceive, defraud, or harm the public or any member thereof;

(10) Knowingly made, or caused to be made, or aided or abetted in the making of, a false
statement in any document executed in connection with the practice of his
profession;

(11) Employed, as a practitioner of medicine or osteopathy in the practice of his
profession in this state, any person not duly licensed or otherwise aided, assisted, or
abetted the unlawful practice of medicine or osteopathy or any other healing art;

(12) Violated or attempted to violate, directly or indirectly, or assisted in or abetted the
violation of, or conspired to violate any provision or term of any medical practice
act, including but not limited to the code of conduct promulgated by the board under
KRS 311.601 or any other valid regulation of the board;

(13) Violated any agreed order, letter of agreement, final order, or emergency order
issued by the board;

(14) Engaged in or attempted to engage in the practice of medicine or osteopathy under a
false or assumed name, or impersonated another practitioner of a like, similar, or
different name;

(15) Obtained a fee or other thing of value on the fraudulent representation that a
manifestly incurable condition could be cured;

(16) Willfully violated a confidential communication;

(17) Had his license to practice medicine or osteopathy in any other state, territory, or
foreign nation revoked, suspended, restricted, or limited or has been subjected to
other disciplinary action by the licensing authority thereof. This subsection shall not
require relitigation of the disciplinary action;

(18) Failed or refused, without legal justification, to practice medicine in a rural area of
this state in violation of a valid medical scholarship loan contract with the trustees
of the rural Kentucky medical scholarship fund;

(19) Given or received, directly or indirectly, from any person, firm, or corporation, any
fee, commission, rebate, or other form of compensation for sending, referring, or
otherwise inducing a person to communicate with a person licensed under KRS
311.530 to 311.620 in his professional capacity or for any professional services not
actually and personally rendered; provided, however, that nothing contained in this
subsection shall prohibit persons holding valid and current licenses under KRS
311.530 to 311.620 from practicing medicine in partnership or association or in a
professional service corporation authorized by KRS Chapter 274, as now or
hereinafter amended, or from pooling, sharing, dividing, or apportioning the fees
and moneys received by them or by the partnership, corporation, or association in
accordance with the partnership agreement or the policies of the board of directors
of the corporation or association. Nothing contained in this subsection shall
abrogate the right of two (2) or more persons holding valid and current licenses
under KRS 311.530 to 311.620 to receive adequate compensation for concurrently
rendering professional care to a single patient and divide a fee, if the patient has full
knowledge of this division and if the division is made in proportion to the services
performed and responsibility assumed by each;

(20) Been removed, suspended, expelled, or disciplined by any professional medical
association or society when the action was based upon what the association or
society found to be unprofessional conduct, professional incompetence, malpractice,
or a violation of any provision of KRS Chapter 311. This subsection shall not
require relitigation of the disciplinary action;

(21) Been disciplined by a licensed hospital or medical staff of the hospital, including
removal, suspension, limitation of hospital privileges, failing to renew privileges for
cause, resignation of privileges under pressure or investigation, or other disciplinary
action if the action was based upon what the hospital or medical staff found to be unprofessional conduct, professional incompetence, malpractice, or a violation of any provisions of KRS Chapter 311. This subsection shall not require relitigation of the disciplinary action;

(22) Failed to comply with the requirements of KRS 213.101, 311.782, or 311.783 or failed to submit to the Vital Statistics Branch in accordance with a court order a complete report as described in KRS 213.101;

(23) Failed to comply with any of the requirements regarding making or maintaining medical records or documents described in KRS 311.7704 or 311.7707;

(24) Failed to comply with the requirements of KRS 311.7705 or 311.7706;

(25) Been convicted of female genital mutilation under KRS 508.125, which shall result in mandatory revocation of a license;

or

(26) As provided in KRS 311.824(2), been convicted of a violation of KRS 311.823(2);

(27) Failed to comply with the requirements of Section 1 of this Act.

Section 3. KRS 311.990 is amended to read as follows:

(1) Any person who violates KRS 311.250 shall be guilty of a violation.

(2) Any college or professor thereof violating the provisions of KRS 311.300 to 311.350 shall be civilly liable on his bond for a sum not less than one hundred dollars ($100) nor more than one thousand dollars ($1,000) for each violation, which may be recovered by an action in the name of the Commonwealth.

(3) Any person who presents to the county clerk for the purpose of registration any license which has been fraudulently obtained, or obtains any license under KRS 311.380 to 311.510 by false or fraudulent statement or representation, or practices podiatry under a false or assumed name or falsely impersonates another practitioner or former practitioner of a like or different name, or aids and abets any person in the practice of podiatry within the state without conforming to the requirements of KRS
311.380 to 311.510, or otherwise violates or neglects to comply with any of the
provisions of KRS 311.380 to 311.510, shall be guilty of a Class A misdemeanor.
Each case of practicing podiatry in violation of the provisions of KRS 311.380 to
311.510 shall be considered a separate offense.

(4) Each violation of KRS 311.560 shall constitute a Class D felony.

(5) Each violation of KRS 311.590 shall constitute a Class D felony. Conviction under
this subsection of a holder of a license or permit shall result automatically in
permanent revocation of such license or permit.

(6) Conviction of willfully resisting, preventing, impeding, obstructing, threatening, or
interfering with the board or any of its members, or of any officer, agent, inspector,
or investigator of the board or the Cabinet for Health and Family Services, in the
administration of any of the provisions of KRS 311.550 to 311.620 shall be a Class
A misdemeanor.

(7) Each violation of KRS 311.375(1) shall, for the first offense, be a Class B
misdemeanor, and, for each subsequent offense shall be a Class A misdemeanor.

(8) Each violation of KRS 311.375(2) shall, for the first offense, be a violation, and, for
each subsequent offense, be a Class B misdemeanor.

(9) Each day of violation of either subsection of KRS 311.375 shall constitute a
separate offense.

(10) (a) Any person who intentionally or knowingly performs an abortion contrary to
the requirements of KRS 311.723(1) shall be guilty of a Class D felony; and
(b) Any person who intentionally, knowingly, or recklessly violates the
requirements of KRS 311.723(2) shall be guilty of a Class A misdemeanor.

(11) (a) 1. Any physician who performs a partial-birth abortion in violation of KRS
311.765 shall be guilty of a Class D felony. However, a physician shall
not be guilty of the criminal offense if the partial-birth abortion was
necessary to save the life of the mother whose life was endangered by a
physical disorder, illness, or injury.

2. A physician may seek a hearing before the State Board of Medical Licensure on whether the physician's conduct was necessary to save the life of the mother whose life was endangered by a physical disorder, illness, or injury. The board's findings, decided by majority vote of a quorum, shall be admissible at the trial of the physician. The board shall promulgate administrative regulations to carry out the provisions of this subparagraph.

3. Upon a motion of the physician, the court shall delay the beginning of the trial for not more than thirty (30) days to permit the hearing, referred to in subparagraph 2. of this paragraph, to occur.

(b) Any person other than a physician who performs a partial-birth abortion shall not be prosecuted under this subsection but shall be prosecuted under provisions of law which prohibit any person other than a physician from performing any abortion.

(c) No penalty shall be assessed against the woman upon whom the partial-birth abortion is performed or attempted to be performed.

(12) (a) Except as provided in subsection (12) of Section 1 of this Act, any person who intentionally or recklessly performs an abortion upon a minor without obtaining the required consent pursuant to Section 1 of this Act shall be guilty of a Class D felony.

(b) Except as provided in paragraph (a) of this subsection, any person who intentionally performs an abortion with knowledge that, or with reckless disregard as to whether, the person upon whom the abortion is to be performed is an unemancipated minor, and who intentionally or knowingly fails to conform to any requirement of KRS 311.732 is guilty of a Class A misdemeanor.
Any person who negligently releases information or documents which are confidential under KRS 311.732 is guilty of a Class B misdemeanor.

Any person who performs an abortion upon a married woman either with knowledge or in reckless disregard of whether KRS 311.735 applies to her and who intentionally, knowingly, or recklessly fails to conform to the requirements of KRS 311.735 shall be guilty of a Class D felony.

Any person convicted of violating KRS 311.750 shall be guilty of a Class B felony.

Any person who violates KRS 311.760(2) shall be guilty of a Class D felony.

Any person who violates KRS 311.770 shall be guilty of a Class D felony.

Except as provided in KRS 311.787(3), any person who intentionally violates KRS 311.787 shall be guilty of a Class D felony.

A person convicted of violating KRS 311.780 shall be guilty of a Class C felony.

Except as provided in KRS 311.782(6), any person who intentionally violates KRS 311.782 shall be guilty of a Class D felony.

Any person who violates KRS 311.783(1) shall be guilty of a Class B misdemeanor.

Any person who violates KRS 311.7705(1) is guilty of a Class D felony.

Any person who violates KRS 311.7706(1) is guilty of a Class D felony.

Except as provided in KRS 311.731(7), any person who violates KRS 311.731(2) shall be guilty of a Class D felony.

Any physician, physician assistant, advanced practice registered nurse, nurse, or other healthcare provider who intentionally violates KRS 311.823(2) shall be guilty of a Class D felony. As used in this subsection, "healthcare provider" has the same meaning as in KRS 311.821.

Any person who violates KRS 311.810 shall be guilty of a Class A
misdemeanor.

(26) Any professional medical association or society, licensed physician, or hospital or hospital medical staff who shall have violated the provisions of KRS 311.606 shall be guilty of a Class B misdemeanor.

(27) Any administrator, officer, or employee of a publicly owned hospital or publicly owned health care facility who performs or permits the performance of abortions in violation of KRS 311.800(1) shall be guilty of a Class A misdemeanor.

(28) Any person who violates KRS 311.905(3) shall be guilty of a violation.

(29) Any person who violates the provisions of KRS 311.820 shall be guilty of a Class A misdemeanor.

(30) (a) Any person who fails to test organs, skin, or other human tissue which is to be transplanted, or violates the confidentiality provisions required by KRS 311.281, shall be guilty of a Class A misdemeanor.

(b) Any person who has human immunodeficiency virus infection, who knows he is infected with human immunodeficiency virus, and who has been informed that he may communicate the infection by donating organs, skin, or other human tissue who donates organs, skin, or other human tissue shall be guilty of a Class D felony.

(31) Any person who sells or makes a charge for any transplantable organ shall be guilty of a Class D felony.

(32) Any person who offers remuneration for any transplantable organ for use in transplantation into himself shall be fined not less than five thousand dollars ($5,000) nor more than fifty thousand dollars ($50,000).

(33) Any person brokering the sale or transfer of any transplantable organ shall be guilty of a Class C felony.

(34) Any person charging a fee associated with the transplantation of a transplantable organ in excess of the direct and indirect costs of procuring,
distributing, or transplanting the transplantable organ shall be fined not less than fifty thousand dollars ($50,000) nor more than five hundred thousand dollars ($500,000).

(35) Any hospital performing transplantable organ transplants which knowingly fails to report the possible sale, purchase, or brokering of a transplantable organ shall be fined not less than ten thousand dollars ($10,000) or more than fifty thousand dollars ($50,000).

(36) (a) Any physician or qualified technician who violates KRS 311.727 shall be fined not more than one hundred thousand dollars ($100,000) for a first offense and not more than two hundred fifty thousand dollars ($250,000) for each subsequent offense.

(b) In addition to the fine, the court shall report the violation of any physician, in writing, to the Kentucky Board of Medical Licensure for such action and discipline as the board deems appropriate.

(37) Any person who violates KRS 311.691 shall be guilty of a Class B misdemeanor for the first offense, and a Class A misdemeanor for a second or subsequent offense. In addition to any other penalty imposed for that violation, the board may, through the Attorney General, petition a Circuit Court to enjoin the person who is violating KRS 311.691 from practicing genetic counseling in violation of the requirements of KRS 311.690 to 311.700.

(38) Any person convicted of violating KRS 311.728 shall be guilty of a Class D felony.

(39) (a) A person who intentionally, knowingly, or recklessly violates Sections 5 to 11 of this Act is guilty of a Class D felony.

(b) No criminal penalty may be assessed against a pregnant patient upon whom a drug-induced abortion is attempted, induced, or performed.

Section 4. KRS 213.101 is amended to read as follows:
(1) Each abortion as defined in KRS 213.011 which occurs in the Commonwealth, regardless of the length of gestation, shall be reported to the Vital Statistics Branch by the person in charge of the institution within three (15) days after the end of the month in which the abortion occurred. If the abortion was performed outside an institution, the attending physician shall prepare and file the report within three (15) days after the end of the month in which the abortion occurred.

(2) The report shall include all the information the physician is required to certify in writing or determine under KRS 311.731, 311.7704, 311.7705, 311.7706, 311.7707, 311.774, 311.782, and 311.783, Sections 1, 8, and 9 of this Act, and at a minimum:

(a) The full name and address of the physician who performed the abortion or provided the abortion-inducing drug as defined in Section 5 of this Act;

(b) The address at which the abortion was performed or the address at which the abortion-inducing drug was provided by a qualified physician, or the method of obtaining the abortion-inducing drug if not provided by a qualified physician, including mail order, internet order, or by a telehealth provider in which case identifying information for the pharmacy, Web site address, or the telemedicine provider shall be included;

(c) The names, serial numbers, National Drug Codes, lot numbers, and expiration dates of the specific abortion-inducing drugs that were provided to the pregnant patient and the dates each were provided;

(d) The full name and address of the referring physician, agency, or service, if any;

(e) The pregnant patient's city or town, county, state, country of residence, and zip code;

(f) The pregnant patient's age, race, and ethnicity;
(g) The age or approximate age of the father, if known;

(h) The total number and dates of each previous pregnancy, live birth, and abortion of the pregnant patient;

(i) The probable gestational and post-fertilization ages of the unborn child, the methods used to confirm the gestational and post-fertilization ages, and the date determined;

(j) A list of any pre-existing medical conditions of the pregnant patient that may complicate her pregnancy, if any, including hemorrhage, infection, uterine perforation, cervical laceration, retained products, or any other condition;

(k) Whether the fetus was delivered alive and the length of time the fetus survived;

(l) Whether the fetus was viable and, if viable, the medical reason for termination;

(m) Whether a pathological examination of the fetus was performed;

(n) Whether the pregnant patient returned for a follow-up examination, the date and results of any such follow-up examination, and what reasonable efforts were made by the qualified physician to encourage the patient to reschedule a follow-up examination if the appointment was missed;

(o) Whether the woman suffered any complications or adverse events as defined in Section 5 of this Act and what specific complications or adverse events occurred, and any follow-up treatment provided as required by Section 25 of this Act;

(p) Whether the pregnant patient was Rh negative and, if so, was provided with an Rh negative information fact sheet and treated with the prevailing medical standard of care to prevent harmful fetal or child outcomes or Rh incompatibility in future pregnancies;
(q) The amount billed to cover the treatment for specific complications or adverse events, including whether the treatment was billed to Medicaid, private insurance, private pay, or other method. This should include ICD-10 codes reported and charges for any physician, hospital, emergency room, prescription or other drugs, laboratory tests, and any other costs for treatment rendered;

(r) The reason for the abortion, if known, including abuse, coercion, harassment, or trafficking; and

(s) Whether the pregnant patient was tested for sexually transmitted diseases when providing the informed consent required in KRS 311.725 and Section 8 of this Act twenty-four (24) hours before the abortion procedure or tested at the time of the abortion procedure, and if the pregnant patient tested positive, was treated or referred for treatment and follow-up care [but shall not include information which will identify the physician, woman, or man involved].

(3) The report shall not contain:

(a) The name of the pregnant patient;

(b) Common identifiers such as a Social Security number and motor vehicle operator's license number; and

(c) Any other information or identifiers that would make it possible to ascertain the patient's identity.

(4) If a person other than the physician described in this subsection makes or maintains a record required by Section 1 of this Act, KRS 311.7704, 311.7705, 311.7706, or 311.7707 on the physician's behalf or at the physician's direction, that person shall comply with the reporting requirement described in this subsection as if the person were the physician.

(5) Each prescription issued for an abortion-inducing drug as defined in Section
5 of this Act[RU 486, cytotec, pitocin, mifeprx, misoprostol, or any other drug or combination of drugs] for which the primary indication is the induction of abortion as defined in KRS 213.011 shall be reported to the Vital Statistics Branch within three (3)[fifteen (15)] days after the [end of the month in which] the prescription was issued as required by KRS 311.774, but the report shall not include information which will identify the woman involved or anyone who may be picking up the prescription on behalf of the woman.

(6)[(3)] The name of the person completing the report and the reporting institution shall not be subject to disclosure under KRS 61.870 to 61.884.

(7)[(4)] By September 30 of each year, the Vital Statistics Branch shall issue a public report that provides statistics on all data collected, including the type of abortion procedure used, for the previous calendar year compiled from all of the reports covering that calendar year submitted to the cabinet in accordance with this section for each of the items listed in [subsections (1) and (2) of] this section. Each annual report shall also provide statistics for all previous calendar years in which this section was in effect, adjusted to reflect any additional information from late or corrected reports. The Vital Statistics Branch shall ensure that none of the information included in the report could reasonably lead to the identification of any pregnant woman upon whom an abortion was performed or attempted. Each annual report shall be made available on the cabinet's Web site.

(8)[(5)] (a) Any person or institution who fails to submit a report by the end of thirty (30) days following the due date set in [subsections (1) and (2) of] this section shall be subject to a late fee of five hundred dollars ($500) for each additional thirty (30) day period or portion of a thirty (30) day period the report is overdue.

(b) Any person or institution who fails to submit a report, or who has submitted only an incomplete report, more than one (1) year following the due date set in
[subsection (1) and (2) of] this section, may in a civil action brought by the Vital Statistics Branch be directed by a court of competent jurisdiction to submit a complete report within a time period stated by court order or be subject to contempt of court.

(c) Failure by any physician to comply with the requirements of this section, other than filing a late report, or to submit a complete report in accordance with a court order shall subject the physician to KRS 311.595.

(9)[(6)] Intentional falsification of any report required under this section is a Class A misdemeanor.

(10)[(7)] The Vital Statistics Branch shall promulgate administrative regulations in accordance with KRS Chapter 13A to assist in compliance with this section.

(11) (a) The Office of the Inspector General, Cabinet for Health and Family Services, shall annually audit the required reporting of abortion-related information to the Vital Statistics Branch in this section, and in so doing, shall function as a health oversight agency of the Commonwealth for this specific purpose.

(b) The Office of the Inspector General shall ensure that none of the information included in the audit report could reasonably lead to the identification of any pregnant woman upon whom an abortion was performed or attempted.

(c) If any personally identifiable information is viewed or recorded by the Office of the Inspector General in conducting an audit authorized by this subsection, the information held by the Inspector General shall not be subject to the Kentucky Open Records Act, shall be confidential, and shall only be released upon court order.

(d) The Inspector General shall submit a written report to the General Assembly and the Attorney General and present a report of findings in
person to the Interim Joint Committee on Health, Welfare, and Family
Services by October 1 of each year. The reports shall include findings from:

1. The audit required in this subsection, including any identified
   reporting deficiencies; and

2. All abortion facility inspections, including any violations of KRS
   216B.0431 and 216B.0435.

⇒ SECTION 5. A NEW SECTION OF KRS 311.710 TO 311.820 IS CREATED
TO READ AS FOLLOWS:

As used in Sections 5 to 11 of this Act unless the context otherwise requires:

1. "Abortion" has the same meaning as in KRS 311.720;
2. "Abortion-inducing drug" means a medicine, drug, or any other substance or
   combination of substances prescribed or dispensed with the intent of terminating
   the clinically diagnosable pregnancy of a woman, with knowledge that the
   termination will, with reasonable likelihood, cause the death of the unborn child.
   This includes the off-label use of drugs known to have abortion-inducing
   properties, which are prescribed specifically with the intent of causing an
   abortion, such as mifepristone (mifeprex), misoprostol (cytotec), and
   methotrexate. The use of such drugs to induce abortion is also known as
   "medical," "medication," "RU–486," "chemical," "mifeprex regimen," or
   "drug-induced" abortion. This definition does not apply to drugs that may be
   known to cause an abortion but which are prescribed for other medical
   indications (e.g., chemotherapeutic agents, diagnostic drugs, etc.);
3. "Adverse event" means, as defined the Food and Drug Administration (FDA) in
   21 CFR 312.32, any untoward medical occurrence associated with the use of a
   drug in humans, whether or not considered drug related. "Adverse event" does
   not include an adverse event or suspected adverse reaction that, had it occurred
   in a more severe form, might have caused death;
(4) "Associated physician" means a physician who has entered into an associated physician agreement established in Section 16 of this Act;

(5) "Cabinet" means the Cabinet for Health and Family Services;

(6) "Complication" or "abortion complication" means only the following physical or psychological conditions which, in the reasonable medical judgment of a licensed health care professional, arise as a primary or secondary result of an induced abortion: uterine perforation, cervical laceration, infection, vaginal bleeding that qualifies as a Grade 2 or higher adverse event according to the Common Terminology Criteria for Adverse Events, pulmonary embolism, deep vein thrombosis, failure to actually terminate the pregnancy, incomplete abortion (retained tissue), pelvic inflammatory disease, missed ectopic pregnancy, cardiac arrest, respiratory arrest, renal failure, shock, amniotic fluid embolism, coma, death, free fluid in the abdomen, allergic reactions to anesthesia and abortion-inducing drugs, psychological complications as diagnosed that are listed in the current Diagnostic and Statistical Manual of Mental Disorders, and any other "adverse event" as defined by the FDA criteria provided in the MedWatch Reporting System;

(7) "Gestational age" has the same meaning as in KRS 311.7701;

(8) "Hospital" has the same meaning as in KRS 311.720;

(9) "Manufacturer" or "distributor" means an individual or entity that creates, produces, supplies, transports, or sells drugs, including any substances:

(a) Recognized by an official pharmacopoeia or formulary;

(b) Intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease;

(c) Other than food, intended to affect the structure or any function of the body; and

(d) Intended for use as a component of a medicine but not a device or a
component, part, or accessory of a device;

(10) "Physician" has the same meaning as in KRS 311.720;

(11) "Pregnancy" or "pregnant" has the same meaning as in KRS 311.7701;

(12) "Provide" or "provision" means any act of giving, selling, dispensing, administering, transferring possession, delivering, transporting to, or otherwise providing or prescribing an abortion-inducing drug;

(13) "Qualified physician" means a physician who is credentialed and competent to:
   (a) Identify and document a viable intrauterine pregnancy;
   (b) Assess the gestational age of pregnancy and to inform the patient of gestational age-specific risks;
   (c) Diagnose ectopic pregnancy;
   (d) Determine blood type and administer the prevailing medical standard of care to prevent harmful fetal or child outcomes or Rh incompatibility in future pregnancies if a pregnant patient is Rh negative;
   (e) Assess for signs of domestic abuse, reproductive control, human trafficking, and other signals of coerced abortion;
   (f) Provide surgical intervention or has entered into a contract with another qualified physician to provide surgical intervention; and
   (g) Supervise and bear legal responsibility for any agent, employee, or contractor who is participating in any part of the procedure, including but not limited to pre-procedure evaluation and care; and

(14) "Unborn child" has the same meaning as in KRS 311.781.

SECTION 6. A NEW SECTION OF KRS 311.710 TO 311.820 IS CREATED TO READ AS FOLLOWS:

Abortion-inducing drugs shall only be provided to a pregnant person by a qualified physician following procedures established in Sections 7, 8, and 9 of this Act. It shall be unlawful for any manufacturer and distributor, physician, qualified physician, or
any other person to provide any abortion-inducing drug as defined in Section 5 of this
Act to a pregnant person via courier, delivery, or mail service.

(b) Have a signed contract with an associated physician who is credentialed to
handle complications and produce that signed contract, including the name
and phone number of the associated physician, upon the request of the
cabinet and each pregnant patient.

(2) A qualified physician providing an abortion-inducing drug as defined in Section
5 of this Act shall examine the patient in person and, prior to providing an
abortion-inducing drug, shall:
(a) Independently verify that a pregnancy exists;
(b) Determine the patient's blood type and, if the patient is Rh negative, provide
the patient with an Rh negative information fact sheet and offer to provide
treatment with the prevailing medical standard of care to prevent harmful
fetal or child outcomes or Rh incompatibility in future pregnancies at the
time of the abortion;
(c) Inform the patient that the remains of the unborn child may be visible in
the process of completing the abortion; and
(d) Document, in the patient's medical chart, the gestational age and
intrauterine location of the pregnancy, and whether the patient received
treatment for Rh negativity, as diagnosed, by the most accurate standard of
medical care.
(3) (a) The qualified physician or an agent of the qualified physician providing any abortion-inducing drug as defined in Section 5 of this Act shall schedule a follow-up visit for the patient for approximately seven (7) to fourteen (14) days after administration of the abortion-inducing drug to confirm that the pregnancy is completely terminated and to assess any degree of bleeding.

(b) The qualified physician shall make all reasonable efforts to ensure that the patient returns for the scheduled appointment.

(c) A brief description of the efforts made to comply with this subsection, including the date, time, and identification by name of the person making such efforts, shall be included in the patient's medical record.

 ➔ SECTION 8. A NEW SECTION OF KRS 311.710 TO 311.820 IS CREATED TO READ AS FOLLOWS:

(1) An abortion-inducing drug as defined in Section 5 of this Act shall not be provided to a pregnant patient without the informed consent of the patient. Informed consent shall be obtained at least twenty-four (24) hours before the abortion-inducing drug is provided to a pregnant patient, except if, in the reasonable medical judgment of the qualified physician, compliance with this subsection would pose a risk of:

(a) The death of the pregnant patient; or

(b) The substantial and irreversible physical impairment of a major bodily function, not including psychological or emotional conditions, of the pregnant patient.

(2) A qualified physician shall use a form created by the cabinet to obtain the consent required prior to providing an abortion-inducing drug as defined in Section 5 of this Act and submit the completed form to the cabinet.

(3) A consent form is not valid and consent is not sufficient, unless:

(a) The patient initials each entry, list, description, or declaration required to be
on the consent form:

(b) The patient signs the consent statement; and

c) The qualified physician signs the qualified physician declaration.

(4) The consent form shall include but is not limited to the following:

(a) The probable gestational age of the unborn child as determined by both
   patient history and by ultrasound results used to confirm gestational age;

(b) A detailed description of the steps to complete the drug-induced abortion;

(c) A detailed list of the risks related to the specific abortion-inducing drug as
   defined in Section 5 of this Act or drugs to be used, including potential
   complications and adverse events as defined in Section 5 of this Act;

(d) If the pregnant patient was Rh negative, the pregnant patient was provided
   with an Rh negative information fact sheet and offered treatment with the
   prevailing medical standard of care to prevent harmful fetal or child
   outcomes or Rh incompatibility in future pregnancies;

(e) That the risks of complications from a chemical abortion, including
   incomplete abortion, increase with advancing gestational age;

(f) That it may be possible to reverse the effects of the abortion-inducing drug
   if desired but that this should be done as soon as possible;

(g) That the patient may see the remains of the unborn child in the process of
   completing the abortion;

(h) That initial studies suggest that children born after reversing the effects of
   the abortion-inducing drug mifepristone have no greater risk of
   birth defects than the general population;

(i) That initial studies suggest that there is no increased risk of maternal
   mortality after reversing the effects of the abortion-inducing drug
   mifepristone;

(j) That information on and assistance with reversing the effects of abortion-
inducing drugs are available in the state-prepared materials and on the
cabinet's Web site;

(k) An "acknowledgment of risks and consent statement" which the pregnant
patient shall sign. The pregnant patient shall initial by each statement and
the statement shall include but is not limited to the following declarations:

1. That the pregnant patient understands that the abortion-inducing
drug regimen or procedure is intended to end the pregnancy and will
result in the death of the unborn child;

2. That the pregnant patient is not being forced to have an abortion, has
the choice not to have the abortion, and may withdraw consent to the
abortion-inducing drug regimen even after it has been provided;

3. That the pregnant patient understands that the abortion-inducing
drug to be provided has specific risks and may result in specific
complications;

4. That the pregnant patient has been given the opportunity to ask
questions about the pregnancy, the development of the unborn child,
alternatives to abortion, the abortion-inducing drug or drugs to be
used, and the risks and complications possible when abortion-
inducing drugs are provided;

5. That the pregnant patient was specifically told that information on the
potential ability of qualified medical professionals to reverse the
effects of a drug-induced abortion is available and where to obtain
information for assistance in locating a medical professional that can
aid in the reversal of a drug-induced abortion;

6. That the pregnant patient has been provided access to printed
materials on informed consent for abortion;

7. That the pregnant patient has been given the name and phone number
of the associated physician who has agreed to provide medical care
and treatment in the event of complications associated with the
abortion-inducing drug regimen or procedure;

8. That the qualified physician will schedule an in-person follow-up visit
for the patient for approximately seven (7) to fourteen (14) days after
providing the abortion-inducing drug or drugs to confirm that the
pregnancy is completely terminated and to assess any degree of
bleeding and other complications;

9. That the pregnant patient has received or been given sufficient
information to give informed consent to the abortion-inducing drug
regimen or procedure; and

10. That the patient has a private right of action to sue the qualified
physician under the laws of Kentucky if the patient feels coerced or
misled prior to obtaining an abortion; and

(l) A qualified physician declaration that states that the qualified physician has
explained the abortion-inducing drug or drugs to be provided, has provided
all of the information required in paragraph (k) of this subsection, and has
answered all of the woman’s questions, shall be signed by the qualified
physician.

⇒ SECTION 9. A NEW SECTION OF KRS 311.710 TO 311.820 IS CREATED
TO READ AS FOLLOWS:

(1) Each abortion-inducing drug as defined in Section 5 of this Act provided to a
pregnant patient shall be reported to the cabinet as required by Section 25 of this
Act.

(2) If a qualified physician provides an abortion-inducing drug as defined in Section
5 of this Act to a pregnant woman for the purpose of inducing an abortion, and if
the qualified physician knows that the woman who uses the abortion-inducing
drug for the purpose of inducing an abortion experiences, during or within fifteen (15) days after the use of the abortion-inducing drug, an adverse event as defined in Section 5 of this Act, the qualified physician shall provide a written report of the adverse event within three (3) days of the event to the federal Food and Drug Administration via the MedWatch reporting system, the cabinet, and the Kentucky Board of Medical Licensure.

(3) Any physician, qualified physician, associated physician, or other healthcare provider who diagnoses or treats a patient, either contemporaneously to or at any time after a drug-induced abortion, for a complication or adverse event as defined in Section 5 of this Act related to the drug-induced abortion shall make a report of the complication or adverse event to the cabinet on a report form provided by the cabinet. The report shall be completed and signed by the physician, qualified physician, or other healthcare provider who diagnosed or treated the complication or adverse event, and transmitted to the cabinet within three (3) days after the diagnosis or treatment was provided. Each report shall include at minimum the information required by Section 4 of this Act.

⇒ SECTION 10. A NEW SECTION OF KRS 311.710 TO 311.820 IS CREATED TO READ AS FOLLOWS:

(1) Nothing in Sections 5 to 11 of this Act shall be construed as creating or recognizing a right to abortion.

(2) It is not the intention of Sections 5 to 11 of this Act to make lawful an abortion that is otherwise unlawful.

(3) Sections 5 to 11 of this Act or any state or federal laws to the contrary, abortion-inducing drugs as defined in Section 5 of this Act shall not be provided in any school facility or on state grounds, including but not limited to elementary and secondary schools and institutions of higher education in Kentucky.

⇒ SECTION 11. A NEW SECTION OF KRS 311.710 TO 311.830 IS CREATED
TO READ AS FOLLOWS:

(1) In addition to the remedies available under the laws in this state, failure to comply with Sections 5 to 11 of this Act shall:

(a) Provide a basis for a civil malpractice action for actual and punitive damages;

(b) Provide a basis for a professional disciplinary action under KRS 411.167; and

(c) Provide a basis for recovery for a pregnant patient's survivors for the wrongful death of the patient under KRS 411.130.

(2) When requested, the court shall allow a patient to proceed using only the patient's initials or a pseudonym and may close any proceedings in the case and enter other protective orders to preserve the privacy of the patient upon whom the drug-induced abortion was attempted, induced, or performed.

(3) If judgment is rendered in favor of the plaintiff, the court shall also render judgment for reasonable attorney's fees in favor of the plaintiff against the defendant.

(4) If judgment is rendered in favor of the defendant and the court finds that the plaintiff's suit was frivolous and brought in bad faith, the court may render judgment for reasonable attorney's fees in favor of the defendant against the plaintiff.

SECTION 12. A NEW SECTION OF KRS CHAPTER 213 IS CREATED TO READ AS FOLLOWS:

(1) The cabinet shall publish printed material and maintain on its Web site the following statement: "Information on the potential ability of qualified medical professionals to reverse the effects of an abortion obtained through the use of abortion-inducing drugs as defined in Section 5 of this Act is available, and shall also include information for assistance in locating a medical professional who
can aid in the reversal of a drug-induced abortion.

(2) On an annual basis, the cabinet shall review and update, if necessary, the statement required in subsection (1) of this section and shall also include information for assistance in locating a medical professional who can aid in the reversal of a drug-induced abortion.

SECTION 13. A NEW SECTION OF KRS CHAPTER 213 IS CREATED TO READ AS FOLLOWS:

(1) The cabinet shall create and distribute the report forms required in Sections 1, 4, 8, 9, 24, 25, and 26 of this Act within sixty (60) days after the effective date of this Act.

(2) The cabinet shall prepare and submit a comprehensive annual statistical report to the General Assembly based upon the data gathered from reports required in Sections 1, 4, 8, 9, 24, 25, and 26 of this Act. The aggregated data shall also be made available to the public by the cabinet in an electronic format.

(3) Reports required in Sections 1, 4, 8, 9, 24, 25, and 26 of this Act shall be deemed public records and shall be provided by the cabinet to the Kentucky Board of Medical Licensure, the Kentucky Board of Pharmacy, state law enforcement offices, and child protective services upon request for use in the performance of their official duties.

(4) Absent a valid court order or judicial subpoena, the cabinet, and any other state department, agency, or office or any employees thereof, shall not compare data concerning drug-induced abortion or drug-induced abortion complications or adverse events as defined in Section 5 of this Act maintained in an electronic or other information system file with data in any other electronic or other information system, the comparison of which could result in identifying, in any manner or under any circumstances, a pregnant patient who is obtaining or seeking to obtain a drug-induced abortion.
(5) Statistical information that may reveal the identity of a pregnant person obtaining or seeking to obtain a drug-induced abortion shall not be maintained by the cabinet or any other state department, agency, or office, or any employee or contractor thereof.

(6) The cabinet shall communicate the reporting requirements in Sections 1, 4, 8, 9, 24, 25, and 26 of this Act to all medical professional organizations, licensed physicians, hospitals, emergency medical service providers, abortion facilities, ambulatory surgical facilities, pharmacies, and other healthcare facilities operating in Kentucky.

SECTION 14. A NEW SECTION OF KRS CHAPTER 315 IS CREATED TO READ AS FOLLOWS:

The Kentucky Board of Pharmacy shall promulgate administrative regulations to create a certification program to oversee and regulate the distribution and dispensing of abortion-inducing drugs as defined in Section 5 of this Act. The program shall be known as the Kentucky Abortion-Inducing Drug Certification Program. The program shall establish certification requirements for manufacturers and distributors as defined in Section 5 of this Act to transport, supply, or sell abortion-inducing drugs; qualified physicians as defined in Section 5 of this Act to provide abortion-inducing drugs to pregnant patients; and pharmacies that dispense abortion-inducing drugs. The certification requirements shall include recognition that abortion-inducing drugs may only be provided to patients by qualified physicians as required in Section 6 of this Act and that abortion-inducing drugs shall not be provided directly to a patient outside of the parameters of Kentucky's Abortion-Inducing Drug Certification Program.

SECTION 15. A NEW SECTION OF KRS CHAPTER 315 IS CREATED TO READ AS FOLLOWS:

(1) The Kentucky Board of Pharmacy shall, at a minimum:

(a) Require completion of the certification process for pharmacies, physicians,
manufacturers, and distributors;

(b) Notify certified pharmacies, manufacturers, and distributors which physicians are certified under the Kentucky Abortion-Inducing Drug Certification Program;

(c) Prohibit shipments of abortion-inducing drugs as defined in Section 5 of this Act to physicians who become decertified from the program;

(d) Audit newly certified pharmacies, physicians, manufacturers, and distributors within ninety (90) calendar days after certification and annually thereafter, to ensure that all processes and procedures are in place and functioning to support the requirements of the Abortion-Inducing Drug Certification Program;

(e) Suspend immediately a pharmacist's, physician's, manufacturer's, or distributor's certification if found to be noncompliant until full compliance is demonstrated; and

(f) Enforce compliance and develop a compliance reporting system.

(2) To be eligible for certification, pharmacies, manufacturers, and distributors of abortion-inducing drugs as defined in Section 5 of this Act shall:

(a) Have either obtained a Kentucky license as a distributor, or a Kentucky permit as a pharmacy or manufacturer;

(b) Only distribute to or fulfill prescriptions requested by certified physicians;

(c) Abide by all applicable standards of the National Association of Boards of Pharmacy (NABP);

(d) For online sales or orders, hold a current pharmacy or pharma domain and abide by all required standards by NABP to maintain the domain;

(e) Follow all other applicable state or federal laws related to the dispensation, distribution, or delivery of legend drugs, including abortion-inducing drugs;

(f) Follow all acceptable processes and procedures to maintain a dispensation,
distribution, or delivery system that is secure, confidential, and follows all
processes and procedures, including those for storage, handling, shipping,
tracking packages, serial numbers, National Drug Codes, lot numbers,
expiration dates, proof of delivery, and controlled returns of abortion-
inducing drugs; and

(g) Only fulfill prescriptions that are accompanied by a patient consent form
required under subsection (3) of this section.

(3) To be eligible for certification to provide abortion-inducing drugs as defined in
Section 5 of this Act, a physician shall:

(a) Be licensed to practice medicine and in good standing in Kentucky;

(b) Examine any patient in-person prior to providing abortion-inducing drugs;

(c) Sign an annual "Dispensing Agreement Form," to be developed and
provided by the board, prior to providing abortion-inducing drugs;

(d) Inform the patient of gestational age-specific risks of using abortion-
inducing drugs;

(e) Assess for signs of domestic abuse, reproductive control, human trafficking,
and other signals of coerced abortion, per current state guidelines;

(f) Inform the patient that studies show babies born following the abortion
reversal process have a rate of birth defects no higher than the general
population;

(g) Inform the patient that studies show that following a reversal process or
otherwise treating a pregnant patient with progesterone during pregnancy
does not lead to increased mortality rates;

(h) Refrain from knowingly supplying abortion-inducing drugs to patients who
present with any of the following:

1. Absence of a pregnancy;

2. Being post-seventy (70) days gestation or post-ten (10) weeks of
pregnancy; or

3. **Risk factors associated with abortion-inducing drugs, including but not limited to:**

   a. A history of ectopic pregnancies;
   
   b. Problems with the adrenal glands near the kidneys;
   
   c. Being treated with long-term corticosteroid therapy;
   
   d. Allergic reactions to abortion-inducing drugs, mifepristone, misoprostol, or similar drugs;
   
   e. Bleeding problems or taking anticoagulant drug products;
   
   f. Inherited porphyria;
   
   g. An intrauterine device in place; or
   
   h. Being Rh negative, requiring treatment with the prevailing medical standard of care to prevent harmful fetal or child outcomes or Rh incompatibility in future pregnancies before providing abortion-inducing drugs;

   (i) Provide or refer for emergency surgical intervention in cases of incomplete abortion, severe bleeding, or other abortion complications or adverse events as defined in Section 5 of this Act, through maintaining hospital admitting privileges or entering into a written agreement with an associated physician as defined in Section 5 of this Act;

   (j) Ensure patient access to medical facilities equipped to provide blood transfusions and resuscitation or other necessary treatments, if necessary;

   (k) Sign, and ensure that the patient signs, all legally required informed-consent material, provide the patient with a copy showing both signatures, and place the original in the patient's medical record and forward to a certified pharmacy, if appropriate;

   (l) Record the serial number, National Drug Code, lot number, and expiration
date from each package of each abortion-inducing drug given to the patient in the patient's medical record;

(m) Submit a written protocol of how efforts will be made to schedule a follow-up appointment with the patient within fourteen (14) days to ensure a completed abortion;

(n) Submit a written protocol of how complications or adverse events as defined in Section 5 of this Act will be handled by the certified physician and submit a copy of a signed contract with an associated physician credentialed to handle certain complications if necessary;

(o) Abide by all applicable state and federal laws regarding medical records retention, confidentiality, and privacy; and

(p) Agree to follow and document compliance with all other legally required conditions for performing an abortion in Kentucky.

SECTION 16. A NEW SECTION OF KRS CHAPTER 315 IS CREATED TO READ AS FOLLOWS:

The Kentucky Board of Pharmacy shall require the following of physicians certified by the Kentucky Abortion-Inducing Drug Certification Program:

(1) Maintain hospital admitting privileges at one (1) or more hospitals in the county or contiguous county where abortion-inducing drugs as defined in Section 5 of this Act will be provided and inform the patient of the hospital or hospitals where the physician holds admitting privileges; or

(2) Enter into a written associated physician agreement as required in Section 7 of this Act, with a physician in the county or contiguous county where abortion-inducing drugs as defined in Section 5 of this Act will be provided. The written agreement shall meet these conditions:

(a) A physician who will be providing an abortion-inducing drug shall notify the patient of the location of the hospital at which the associated physician
has admitting privileges;
(b) The physician shall keep, at the location of his or her practice, a copy of the
written agreement;
(c) The board shall annually submit a copy of the written agreement to each
hospital located in the county or a county that is contiguous to the county
where abortion-inducing drugs will be provided;
(d) The agreement shall be renewed annually; and
(e) The agreement shall include a requirement that the physician provide to the
patient, and require the patient to sign, all legally required informed-
consent material.

SECTION 17. A NEW SECTION OF KRS CHAPTER 315 IS CREATED TO
READ AS FOLLOWS:

(1) The Kentucky Board of Pharmacy shall develop a plan to enforce the Kentucky
Abortion-Inducing Drug Certification Program that includes the following
conditions:
(a) If an individual or entity provides abortion-inducing drugs as defined in
Section 5 of this Act without first seeking certification, the board shall:
1. Immediately report the act to local law enforcement or other
applicable state and local agencies; and
2. Impose a fine of no less than five million dollars ($5,000,000) for
pharmacies, manufacturers, or distributors and two hundred fifty
thousand ($250,000) for physicians;
(b) If a certified pharmacy, manufacturer, distributor, or physician is
determined to be in noncompliance, suspend any certification until
compliance is proven to the satisfaction of the board;
(c) If a current or previously certified pharmacy, manufacturer, or distributor
is found to have intentionally or knowingly violated certification
requirements, or refuses to bring operations into compliance within ninety (90) calendar days, remove certification and prohibit continued provision of abortion-inducing drugs by the pharmacy, manufacturer, or distributor until compliance is demonstrated to the satisfaction of the board;

(d) If a certified pharmacy, manufacturer, distributor, or physician is in non-compliance, suspend all annual recertifications until compliance is demonstrated to the satisfaction of the board; and

(e) If a current or previously certified pharmacy, manufacturer, distributor, or physician is found to have intentionally or knowingly violated Sections 14, 15, or 16 of this Act, or refuses to bring operations into compliance:

1. Immediately suspend the pharmacy's, manufacturer's, distributor's, or physician's certification until full compliance is demonstrated;

2. For certified pharmacies, manufacturers, or distributors, impose fines of not less than one million dollars ($1,000,000) per offense;

3. For certified physicians, impose fines of not less than one hundred thousand dollars ($100,000) per offense;

4. Permanently revoke the certification of the offender if the offender fails to demonstrate compliance within ninety (90) calendar days;

5. Impose remedial actions, which may include additional education, additional reporting, or other actions as required by the board;

6. In the case of a pharmacy, manufacturer, or distributor, recommend sanctioning to the appropriate disciplinary committee of the board;

7. In the case of a licensed physician, report the violation to the Kentucky Board of Medical Licensure;

8. Publicly report any disciplinary actions, consistent with the practices of the board;

9. Permanently revoke the certification of the offender;
10. In the case of a pharmacy, manufacturer, or distributor, recommend permanent revocation of licensure; and

11. In the case of a licensed physician, recommend appropriate sanctioning to the Kentucky Board of Medical Licensure.

(2) Individuals have a private right of action to seek restitution in any court of law with appropriate jurisdiction for any and all damages suffered for violating Sections 14, 15, or 16 of this Act.

⇒ SECTION 18. A NEW SECTION OF KRS CHAPTER 315 IS CREATED TO READ AS FOLLOWS:

(1) The Kentucky Board of Pharmacy shall develop a complaint portal on its Web site for patients, pharmacy, nursing, and medical professionals, and the public to submit information about potential violations of the Kentucky Abortion-Inducing Drug Certification Program.

(2) The portal shall list the names of pharmacies, manufacturers, and distributors that are certified under the program and the physicians that are certified under the program to provide abortion-inducing drugs as defined in Section 5 of this Act.

(3) An individual shall be allowed to make a complaint anonymously on the portal.

(4) The board shall review each complaint and determine a disposition, including referral to another state department, within thirty (30) days.

(5) Confidentiality of the originator of the complaint shall be protected at all times except for intrastate referrals for investigation.

⇒ Section 19. KRS 213.081 is amended to read as follows:

(1) No person shall cremate or cause to be transported for the purpose of cremation the body of any person whose death occurs in the Commonwealth, without first obtaining from the coroner of the county in which the death occurred, a permit stating the cause of death and authorizing the cremation or transportation for
cremation of the body. The permit shall be filed immediately following cremation with the local registrar of vital statistics.

(2) [The provisions of this section shall not apply to the cremation of ] Fetal death remains **shall require the same permit required by subsection (1) of this section** [in the absence of any indication of a criminal act].

(3) **Notwithstanding KRS 367.97514, miscarried fetuses may be cremated by simultaneous cremation.**

Section 20. KRS 213.096 is amended to read as follows:

(1) Each fetal death of twenty (20) completed weeks' gestation or more, calculated from the date last normal menstrual period began to the date of delivery or in which the fetus weighs three hundred fifty (350) grams or more, **or an abortion** which occurs in the Commonwealth, shall be reported on a combination birth-death or stillbirth certificate in accordance with applicable provisions of KRS 213.046 and KRS 213.076. If the fetal death **or abortion** occurs in a hospital, the person in charge of the institution or the person's designated representative shall complete the birth-death or stillbirth certificate, obtain the medical certification, and file the certificate with the state registrar.

(2) The name of the father shall be entered on the birth-death or stillbirth certificate in accordance with the provisions of KRS 213.046.

(3) All abortions shall also be reported in the manner prescribed in KRS 213.101 [and shall not be reported as stillbirths].

Section 21. A new section of KRS 311.710 to 311.820 is created to read as follows:

(1) **For the purposes of this section, "fetal remains" means the biological remains of a human child resulting from the termination of a pregnancy by a surgical or chemical abortion prior to birth or miscarriage.**

(2) (a) **Within twenty-four (24) hours before a surgical or chemical abortion or**
within twenty-four (24) hours of a miscarriage, the healthcare facility or abortion clinic shall disclose to the parent or parents of the fetus, both orally and in writing, the parents' right to determine if they will take responsibility for the final disposition of the fetal remains or relinquish the responsibility for final disposition to the healthcare facility or abortion clinic.

(b) If the procedure is a chemically induced abortion, the mother:

1. Shall be informed that she will expel a fetus after leaving the healthcare facility or abortion clinic;

2. May choose to return the fetal remains to the healthcare facility or abortion clinic for final disposition;

3. Shall be exempted from the requirements of Section 19 of this Act requiring a permit for the purpose of transporting the fetal remains back to the healthcare facility or abortion clinic for final disposition; and

4. Shall be exempted from the requirements of Section 20 requiring an abortion to be reported on a combination birth-death or stillbirth certificate.

(c) After receiving the information required by paragraphs (a) and (b) of this subsection, the parent or parents of the fetus shall inform the healthcare facility or abortion clinic of their choice for the disposition of the fetal remains by electing to either:

1. Relinquish the guardianship of the fetal remains and the responsibility for final disposition of those remains to the guardianship of the healthcare facility or abortion clinic which shall dispose of those remains as they would any other human remains; or

2. Retain the guardianship for the fetal remains and designate that fetal
remains shall be released to the parent or parents for disposition.

The healthcare facility or abortion clinic shall document the parents' decision in the medical record.

(3) The cabinet shall design forms through administrative regulations that document:

(a) The age of the parent or parents of the fetal remains;

(b) In the event that the parents are under eighteen (18) years of age, or have not been emancipated by court order, a consent by their parent or guardian;

(c) A designation of how the fetal remains shall be disposed of and who shall be responsible for the final disposition; and

(d) Any other information required by the cabinet.

(4) A person or entity shall not:

(a) Dispose of a fetus or fetal remains as medical or infectious waste;

(b) Offer money or anything of value for an aborted fetus or fetal remains;

(c) Accept money or anything of value for an aborted fetus or fetal remains; or

(d) Transport, or arrange for the transportation of, fetal remains for any purpose other than:

1. Final disposition by a crematory licensed under KRS Chapter 367;

2. Interment by a funeral establishment licensed under KRS Chapter 316; or

3. Interment by the parent or parents privately in conformance with KRS 381.697 and administrative regulations promulgated by the Cabinet for Health and Family Services.

Section 22. KRS 367.97501 is amended to read as follows:

As used in KRS 367.97501 to 367.97537, unless the context requires otherwise:

(1) "Authorizing agent" means the person legally entitled to order the cremation of the human remains.
(2) "Casket" means a rigid container which is designed for the encasement of human remains constructed of wood, metal, or other material.

(3) "Closed container" means a sealed container or urn in which cremated remains are placed and enclosed in a manner that prevents leakage or spillage of cremated remains or the entrance of foreign material.

(4) "Cremated remains" means the fragments remaining after the cremation process has been completed.

(5) "Cremation" means the heating process that reduces human remains to bone fragments through combustion and evaporation.

(6) "Cremation authorization form" means a form promulgated by administrative regulation of the Attorney General that expresses consent to the decedent's cremation. The form shall include information concerning the parties' rights and responsibilities.

(7) "Cremation chamber" means an enclosed space designed and manufactured for the purpose of cremating human remains.

(8) "Cremation container" means a container in which human remains may be delivered to a crematory for cremation that is:

(a) Rigid enough to support the weight of the corpse, closed, and leakproof;

(b) Composed of a combustible material or other material approved by the crematory authority; and

(c) A proper and dignified covering for the human remains.

(9) "Crematory authority" means the legal entity which is licensed by the Attorney General to operate a crematory and conduct cremations. Crematory authority does not include state university health science centers.

(10) "Crematory" means a fixed building or structure that contains one (1) or more cremation chambers for the reduction of bodies of deceased persons to cremated remains. "Crematory" includes crematorium.
(11) "Crematory operator" means the person in charge of a licensed crematory authority.
(12) "Declaration" has the same meaning as in KRS 367.93101.
(13) "Holding facility" means an area designated for the retention of human remains prior to cremation.
(14) "Human remains" means the body of a deceased person or part of a body or limb that has been removed from a living person, in any state of decomposition, prior to cremation.
(15) "Pathological waste" means human tissues, organs, and blood or body fluids, in liquid or semiliquid form that are removed from a person for medical purposes. "Pathological waste" does not include amputations or fetal remains as defined by Section 21 of this Act.
(16) "Processed remains" means the end result of pulverization, by which the residual from the cremation process is reduced and cleaned leaving only fragments reduced to unidentified dimensions.
(17) "Retort operator" means a person operating a cremation chamber.
(18) "Scattering area or garden" means an area which may be designated by a cemetery and located on a dedicated cemetery property where cremated remains which have been removed from their container can be mixed with or placed on top of the soil or ground cover.
(19) "Temporary container" means a receptacle for cremated remains, usually made of plastic, cardboard, ceramics, plastic film, wood, or metal, designed to prevent the leakage of processed remains or the entrance of foreign materials which will hold the cremated remains until an urn or other permanent container is acquired.

Section 23. KRS 311.715 is amended to read as follows:

(1) As used in this section, "public agency funds" means any money, regardless of the original source of the money, of a public agency.
(2) Public agency funds shall not be used for the purpose of obtaining an abortion or
paying for the performance of an abortion. Public medical facilities may be used for
the purpose of conducting research into or the performance of in-vitro fertilization
as long as such procedures do not result in the intentional destruction of a human
embryo.

(3) Public agency funds shall not be directly or indirectly used, granted, paid, or
distributed to any entity, organization, or individual that performs, induces, refers
for, or counsels in favor of abortions. This subsection shall not apply to funding
available through KRS 205.510 to 205.560 to the minimum extent necessary to
comply with federal conditions for the state's participation in the program
established by KRS 205.510 to 205.560 or to funding that is used to provide
abstinence education in schools.

(4)(2) (a) Public agency funds shall not be directly or indirectly used, granted,
paid, or distributed to any nonpublic entity or organization described in
paragraph (b)3. of this subsection. This paragraph shall not apply to funding
available through KRS 205.510 to 205.560 to the minimum extent necessary
to comply with federal conditions for the state's participation in the program
established by KRS 205.510 to 205.560 or to funding that is used to provide
abstinence education in schools.

(b) Notwithstanding any other state law to the contrary, all federal family
planning funds shall be awarded to eligible individuals, organizations, or
entities applying to be family planning contractors in the following order of
descending priority:

1. Public agencies that directly provide family planning services, including
   state, county, and local community health clinics and federally qualified
   health centers;

2. Nonpublic entities that directly provide basic health services, as
described in 42 U.S.C. sec. 254b(b)(1)(A), including family planning
services; and

3. Nonpublic entities that directly provide only family planning services but do not provide all basic health services as described in 42 U.S.C. sec. 254b(b)(1)(A).

(c) This subsection shall be effective upon repeal of federal regulations prohibiting states from prioritizing recipients of federal Public Health Service Act, Title X Family Planning Program funds.

(5) Nothing in this section shall be deemed to deprive a woman of all appropriate medical care necessary to prevent her physical death.

(6) Nothing in this section shall be construed to allow public funds to pay for in-vitro fertilization procedures performed on any individual patient.

SECTION 24. A NEW SECTION OF KRS 311.710 TO 311.820 IS CREATED TO READ AS FOLLOWS:

(1) A hospital, healthcare facility, or individual physician shall file a written report with the cabinet regarding each patient who comes under the hospital's, healthcare facility's, or physician's care and reports any complication or adverse event as defined under Section 5 of this Act, requires medical treatment, or suffers a death that the attending physician, hospital staff, or facility staff has reason to believe is a primary or secondary result of an abortion. The reports shall be completed by the hospital, healthcare facility, or attending physician who treated the patient, signed by the attending physician, and transmitted to the cabinet within thirty (30) days of the discharge or death of the patient treated for the complication or adverse event.

(2) Each report of a complication or adverse event as defined in Section 5 of this Act, medical treatment, or death following abortion required under this section shall contain at minimum the information required by Section 4 of this Act.

(3) Reports required under this section shall not contain:
(a) The name of the patient;

(b) Common identifiers such as Social Security number or motor vehicle operator's license number; or

(c) Other information or identifiers that would make it possible to identify, in any manner or under any circumstances, a patient who has obtained an abortion and subsequently suffered an abortion complication or adverse event as defined in Section 5 of this Act.

Section 25. KRS 311.774 is amended to read as follows:

(1) Each prescription issued for an abortion-inducing drug as defined in Section 5 of this Act [RU 486, cytotec, pitocin, mifeprex, misoprostol, or any other drug or combination of drugs] for which the primary indication is the induction of abortion as defined in KRS 311.720 shall be reported on a report form provided by the cabinet within three (3) [fifteen (15)] days after [the end of the month in which] the prescription was issued. The report form shall be signed by the qualified physician who provided the abortion-inducing drug and transmitted to the cabinet within three (3) days after the drug was provided. Each report shall include at minimum the information required by Section 4 of this Act.

(2) Information on the potential ability of a physician to reverse the effects of abortion-inducing prescription drugs as defined in Section 5 of this Act for which the primary indication is the induction of abortion, including where additional information about this possibility may be obtained and contact information for assistance in locating a physician who may aid in the reversal, shall be provided with each prescription issued for an abortion-inducing drug [RU 486, cytotec, pitocin, mifeprex, misoprostol, or any other drug or combination of drugs] for which the primary indication is the induction of abortion as defined in KRS 311.720.

(3) For each abortion reported to the Vital Statistics Branch as required by KRS
213.101, the report shall also state whether any abortion complication or adverse event as defined in Section 5 of this Act or medical treatment was known to the provider as a result of the abortion. The report shall be completed and signed by the physician qualified physician or other healthcare provider who diagnosed or treated the complication or adverse event.

(4) The report shall include at a minimum the information required by Section 4 of this Act and:

(a) Whether a complication or adverse event as defined in Section 5 of this Act occurred during the abortion procedure or while the pregnant patient was still at the facility where the abortion was performed and the level of intervention required to attend to the complication or adverse event:

1. Emergency medical services;
2. Stabilization on site;
3. Transport to another medical facility;
4. Urgent care follow-up; and
5. Primary care provider;

(b) The date the pregnant patient presented for diagnosis or treatment for the complication or adverse event;

(c) Whether the complication or adverse event was previously managed by the qualified physician who provided the abortion-inducing drug as defined in Section 5 of this Act or a backup qualified physician;

(d) The amount billed to cover the treatment for specific complications, including whether the treatment was billed to Medicaid, private insurance, private pay, or other method. This should include the ICD-10 codes reported and charges for any physician, hospital, emergency room, prescription or other drugs, laboratory tests, and any other costs for treatment rendered; and
(e) A list of complications, adverse events, or treatments that occurred, a list of any emergency transfers, and any follow-up treatment provided including whether any additional drugs were provided in order to complete the drug-induced abortion. [Abortion complications to be reported shall include only the following physical or psychological conditions arising from the induction or performance of an abortion:

(a) Uterine laceration;
(b) Cervical laceration;
(c) Infection;
(d) heavy bleeding that causes symptoms of hypovolemia or the need for a blood transfusion;
(e) Pulmonary embolism;
(f) Deep vein thrombosis;
(g) Failure to terminate the pregnancy;
(h) Incomplete abortion or retained tissue;
(i) Pelvic inflammatory disease;
(j) Missed ectopic pregnancy;
(k) Cardiac arrest;
(l) Respiratory arrest;
(m) Renal failure;
(n) Shock;
(o) Amniotic fluid embolism;
(p) Coma;
(q) Placenta Previa in subsequent pregnancies;
(r) Pre-term delivery in subsequent pregnancies;
(s) Free fluid in the abdomen;
(t) Hemolytic reaction due to the administration of ABO incompatible blood or
blood products;

(u) Hypoglycemia occurring while the patient is being treated at the abortion facility;

(v) allergic reaction to anesthesia or abortion-inducing drugs;

(w) Psychological complications, including depression, suicidal ideation, anxiety, and sleeping disorders;

(x) Death; and

(y) Any other adverse event as defined by criteria provided in the Food and Drug Administration Safety Information and Adverse Event Reporting Program.]

Section 26. KRS 311.783 is amended to read as follows:

(1) Except in a medical emergency that prevents compliance with this section, no physician shall intentionally perform or induce or intentionally attempt to perform or induce an abortion on a pregnant woman unless, prior to the performance or inducement of the abortion or the attempt to perform or induce the abortion, the physician determines, in the physician's reasonable medical judgment, the unborn child's probable post-fertilization age. The physician shall make that determination after making inquiries of the pregnant woman and performing any medical examinations or tests of the pregnant woman the physician considers necessary as a reasonably prudent physician, knowledgeable about the case and medical conditions involved, would consider necessary to determine the unborn child's probable post-fertilization age.

(2) Except in a medical emergency that prevents compliance with this section, no physician shall intentionally perform or induce or intentionally attempt to perform or induce an abortion on a pregnant woman after the unborn child reaches the probable post-fertilization age of twenty (20) weeks without first entering the determination made in subsection (1) of this section and the associated findings of the medical examination and tests in the medical record of the pregnant woman.
The state Board of Medical Licensure shall suspend a physician's license to practice medicine in this state for a period of not less than six (6) months if the physician violates this section.

The physician shall submit a report on a form provided by the cabinet a minimum the information required by Section 4 of this Act and:

(a) The unborn child's probable post-fertilization age determined by the physician; and

(b) The results of inquiries of the pregnant woman and any medical examinations or tests performed.

Section 27. KRS 315.990 is amended to read as follows:

(1) Except for the provisions of KRS 315.320, any person violating any provision of KRS Chapter 315 shall be fined for each offense not less than one hundred dollars ($100) nor more than one thousand dollars ($1,000) or imprisoned in the county jail for not more than six (6) months, or both. Each week that any provision of KRS 315.020, 315.030, or 315.035 is violated shall also constitute a separate offense.

(2) Any person convicted of willfully resisting, preventing, impeding, obstructing, threatening, or interfering with the officers, agents, or inspectors of the board in the administration of the provisions of this chapter shall be guilty of a Class A misdemeanor.

(3) The board may levy an administrative fine not to exceed five thousand dollars ($5,000) for each offense, for any violation of KRS 315.121. All such fines shall be deposited to the credit of the licensing board to be used by the board in carrying out the provisions of this chapter.

(4) The board may refuse to issue or renew a permit, or may suspend, temporarily suspend, revoke, fine, or reasonably restrict any permit holder for any violation of KRS 315.0351. Any administrative fine levied by the board shall not exceed five thousand dollars ($5,000) for any violation of KRS 315.0351. All such fines shall
be deposited to the credit of the licensing board to be used by the Board of Pharmacy in carrying out the provisions of this chapter.

(5) For a violation of KRS 315.320, the Board of Pharmacy may, in addition to any other civil or criminal penalty, levy an administrative fine not exceeding one hundred thousand dollars ($100,000). All such fines shall be deposited to the credit of the Board of Pharmacy in carrying out the provisions of this chapter.

(6) (a) Any person who intentionally, knowingly, or recklessly violates Sections 14 to 18 of this Act is guilty of a Class D felony.

(b) Any person who violates Sections 14 to 18 of this Act shall be fined not more than one million dollars ($1,000,000).

(c) Notwithstanding KRS 440.200, the Attorney General may demand from the Governor of any other state the surrender of any person found in the other state who is charged in Kentucky with the crime of violating Sections 14 to 18 of this Act. The provisions for extradition under this subsection shall apply to any such demand even if the person whose surrender is demanded was not in Kentucky at the time of the commission of the crime. Neither the demand, the oath, nor any proceedings for extradition pursuant to this section need state or show that the person whose surrender is demanded has fled from justice, or at the time of the commission of the crime was in Kentucky or the other state.

SECTION 28. A NEW SECTION OF KRS 311.710 TO 311.820 IS CREATED TO READ AS FOLLOWS:

(1) The General Assembly of the Commonwealth of Kentucky, by resolution, may appoint one (1) or more of its members who sponsored or cosponsored Sections 1 to 27 of this Act in his or her official capacity to intervene as a matter of right in any case to which the constitutionality of Sections 1 to 27 of this Act is challenged; or
(2) The Attorney General may bring an action to enforce compliance with Sections 1 to 27 of this Act or intervene as a matter of right in any case in which the constitutionality of Sections 1 to 27 of this Act is challenged.

Section 29. If any provision of this Act or the application thereof to any person or circumstance is held invalid, the invalidity shall not affect the other provisions or applications of the Act that can be given effect without the invalid provision or application, and to this end the provisions of this Act are severable.

Section 30. This Act may be cited as the Humanity in Healthcare Act of 2022.

Section 31. Whereas the Commonwealth of Kentucky has a paramount interest in protecting all human life, an emergency is declared to exist, and this Act takes effect upon its passage and approval by the Governor or upon its otherwise becoming law.